OLINVYK

Peak

oliceridine

Trevena
NDAINTRAVENOUSSOLUTION
Approved
Aug 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Mechanism of Action

mu-opioid receptor. The principal therapeutic action of oliceridine is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oliceridine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory, and…

Indications (1)

for whom alternative treatments are inadequate

Clinical Trials (2)

NCT02815709Phase 3Completed

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy

Started May 2016
418 enrolled
Acute Pain
NCT02820324Phase 3Completed

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty

Started May 2016
407 enrolled
Acute Pain

Loss of Exclusivity

LOE Date
Mar 23, 2032
73 months away
Patent Expiry
Mar 23, 2032

Patent Records (5)

Patent #ExpiryTypeUse Code
11077098
Mar 23, 2032
SubstanceProduct
U-2986
11931350
Mar 23, 2032
Substance
U-2986
8835488
Mar 23, 2032
SubstanceProduct
U-2986
9309234
Mar 23, 2032
SubstanceProduct
U-2986
9642842
Mar 23, 2032
Product
U-2986
Company
Trevena
Trevena
PA - Chesterbrook
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers